During the meeting with SMA-DER Vice Chairman, Ece Soyer Demir and General Secretary Mehmet Demir, Social Security Institution President, İsmail Yılmaz and SSI General Health Insurance General Manager, Dr. Mustafa Özderyol on Friday, September 4, 2020 expressed the problems of the patients and their relatives, and asked questions about current problems.
1.For Type 1 patients who continue to use Spinraza, the usage principles for the 11th dose and after are not yet clear. Families wonder when the Health Implementation Notification will be announced and its content.
1. While determining the principles of use of Spinraza, our Scientific Committee stated that they did not have a very long-term prediction and they would make an evaluation and make a decision in line with the data from physicians. The Scientific Committee will announce as soon as possible, I don't think the criteria will be any more difficult than what is now.
PGD (Preimplantation Genetic Diagnosis)
1. We are working with the Ministry of Health on this issue, we determine which diseases will be covered. SMA is definitely included in these diseases, we will be operational by the end of the year.